In this talk, Brianna Jayanthi, Senior Synthetic Biologist, discusses:
- The application of synthetic biology alongside computational methodologies to improve the efficiency and stability of lentiviral vector production.
- The development of clonal, suspension HEK293T-based packaging and producer cell lines for the inducible production of VSV-G pseudotyped lentiviral vectors, aiming to simplify the manufacturing process.
- How mid-E8 TU/mL titers are achieved across multiple CAR transgenes through engineered plasmids for tightly regulated gene expression and the use of a proprietary hyperactive transposase.
- The strategic advantages provided by the LV Edge System, including scalability, reduced process complexity, and the elimination of the need for GMP-grade plasmids, potentially leading to more cost-effective cell and gene therapies.